logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

More hospitals aspire to become CAR-T centers

Source: IM Medical Publimas Digital s.l.

The Ministry of Health and the Autonomous Communities have met to assess the suitability of new candidates to administer this type of therapy.

During the Plenary of the Interterritorial Council of the National Health System held last May, the first phase of designation of the centers that opted for the use of drugs with CAR-T therapies was resolved.

Thus, the Hospital Clínic de Barcelona, ??the Gregorio Marañón University Hospital, the Vall d´Hebron Hospital, the Hospital Universitari i Politècnic La Fe, the Salamanca Assistance Complex, the Virgen del Rocío University Hospital in Seville, the Valencia University Hospital and the Hospital de la Santa Creu and Sant Pau were chosen for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBDCG) or with acute lymphoblastic leukemia (ALL) of refractory B-cell in the SNS.

In addition, for both treatments (ALL and LBDCG), two additional centers were appointed with the condition that they will only use CAR-T medications in the event that the activity exceeds the centers that are designated: the ICO Hospital Duran i Reynals and the ICO Hospital Germans Trias i Pujol.

Likewise, the centers chosen for the treatment of pediatric patients with acute lymphoblastic leukemia of refractory B cells in the SNS were the Hospital del Niño Jesús, the Hospital Sant Joan de Déu and the Vall d´Hebron Hospital. Likewise, the University Hospital La Paz in Madrid was proposed as an additional center in pediatrics in the event that the activity exceeds the centers that are designated.

But the list is not closed. In response to the commitment of the Ministry of Health to periodically evaluate hospital applications announced by the communities, new centers have been introduced to carry out this type of therapy. Some of them repeat after being rejected in the first round, while others apply for designation for the first time. At the moment the final resolution is unknown, which was discussed on Tuesday during a meeting that brought together the Ministry and the Autonomous Communities, although it is expected to be announced during the next few days.

 

Related entries

21 October, 2025

The geopolitical context presents Spain with a great opportunity to attract investment in the biopharmaceutical sector.


Leer más
14 October, 2025

“Spain has a great opportunity in the biopharmaceutical sector, but it must review its policies to maintain and increase its potential and attract investment in R&D and in industrial and digital assets.”


Leer más
7 October, 2025

Spain consolidates its leadership in clinical trials with new guidelines promoting innovation, digitalisation and sustainability in hospital pharmacy


Leer más

Recent Posts

  • The geopolitical context presents Spain with a great opportunity to attract investment in the biopharmaceutical sector.
  • “Spain has a great opportunity in the biopharmaceutical sector, but it must review its policies to maintain and increase its potential and attract investment in R&D and in industrial and digital assets.”
  • Spain consolidates its leadership in clinical trials with new guidelines promoting innovation, digitalisation and sustainability in hospital pharmacy
  • Innovation and data at the service of clinical research
  • Spain, European leader in clinical trials against cancer thanks to the agility and ‘atomisation’ of research groups

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.